免疫检查点抑制剂（ICI）相关心脏毒性是一种相对罕见的与免疫相关的不良反应（irAEs），其病死率较高。国内外研究中对不同免疫检查点抑制剂的替代缺乏明确建议。本文报告了一例鳞状非小细胞肺癌（鳞状NSCLC）患者，在接受PD-1抑制剂治疗后出现心脏毒性反应，随后改用PD-L1抑制剂继续治疗。经过四个疗程的免疫治疗后观察到显著效益，并且治疗开始后未再发生心脏毒性。这个病例表明，心肌损伤可以在转换为PD-L1抑制剂后得到改善，抗肿瘤免疫治疗是有效的。这一结果对于优化癌症患者的免疫治疗管理方案可能具有重要意义。版权所有 © 2023 Wu, Li, Cui and Zhang.

Immune checkpoint inhibitor (ICI)-associated cardiotoxicity is a relatively uncommon immune-related adverse effects (irAEs) with a high mortality rate. There are few recommendations for the replacement of different immune checkpoint inhibitors in domestic and international reports.We report a case of a patient with squamous non-small cell lung carcinoma (squamous NSCLC) who developed cardiotoxicity after being treated with a programmed death-1 (PD-1) inhibitor and then changed to a PD-L1 inhibitor to continue the treatment. A significant benefit was observed after four cycles of immunotherapy, and no further cardiotoxicity occurred after the treatment was started.This case demonstrates that myocardial damage induced by tislelizumab (PD-1 inhibitor) can be improved after switching to sugemalimab (PD-L1 inhibitor) and that antitumor immunotherapy is effective. This result may have important implications for optimizing immunotherapy management regimens in cancer patients.Copyright © 2023 Wu, Li, Cui and Zhang.